MedTrace Logo

A Clinical Study on Efficacy & Safety Profile of Propionyl-L-carnitine Tablets for Peripheral Arterial Diseases

NCT00809497 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 239

Last updated 2012-03-29

No results posted yet for this study

Summary

The main objective of this study is to evaluate the effectiveness and safety of the propionyl-L-carnitine hydrochloride tablets among Chinese population in comparison with the placebo, for treatment of the peripheral arterial diseases (intermittent claudication) with oral supplementation of 2g daily for a 4 months continuous administration.

Conditions

  • Peripheral Arterial Disease

Interventions

DRUG

Propionyl-L-carnitine Tablets

500mg tablets, oral administration of 2g daily

Sponsors & Collaborators

  • Nanjing Medical University

    collaborator OTHER

  • Lee's Pharmaceutical Limited

    lead INDUSTRY

Principal Investigators

  • Jianxin Li, MD · Xuanwu Hospital, Beijing

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-09-30
Completion
2011-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00809497 on ClinicalTrials.gov